Skip to main content
Smart Investors Daily
EN

NYSE · ENOV

Enovis Corporation

Industrials · Industrial - Machinery

$20.89

Up+$3.54 (+16.95%)

Updated Nov 4, 2026, 4:56 PM

SID Score

4.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.59B
P/E ratio
-1.17
Dividend yield
0.00%
52-week range
$16.70 – $31.67
Volume
1.94M
Avg. volume
806.57K

Price performance · ENOV

ENOV price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

ENOV closed at $20.89 after 21 trading sessions, up 14.78% for the selected period.

Last close
$20.89
Period change
+14.78%
Period low
$17.43
Period high
$22.81
Daily close
View OHLC price history
ENOV OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$20.63$21.53$20.34$20.891.94M
Nov 2, 2026$20.37$21.67$20.37$20.622.49M
Oct 30, 2026$22.17$22.26$19.83$19.912.52M
Oct 29, 2026$22.12$22.84$21.88$22.811.3M
Oct 28, 2026$21.49$22.285$21.45$21.911.18M
Oct 27, 2026$21.14$22.13$20.61$21.542.38M
Oct 26, 2026$21.10$21.265$20.74$21.16905.91K
Oct 23, 2026$21.39$21.70$20.86$21.08954.3K
Oct 22, 2026$20.99$21.73$20.79$21.591.3M
Oct 21, 2026$20.66$21.49$20.485$20.811.2M
Oct 20, 2026$20.00$20.89$19.89$20.691.19M
Oct 19, 2026$19.53$20.15$19.43$19.871.62M
Oct 16, 2026$19.64$19.78$19.36$19.591.45M
Oct 15, 2026$18.76$19.44$18.42$19.351.29M
Oct 14, 2026$18.74$18.85$18.235$18.571.14M
Oct 13, 2026$18.50$19.12$18.175$18.991.41M
Oct 12, 2026$17.47$18.40$17.36$18.25910.92K
Oct 9, 2026$17.60$17.89$17.145$17.691.15M
Oct 8, 2026$17.35$17.63$16.70$17.432.31M
Oct 7, 2026$18.03$18.13$17.53$17.611.29M
Oct 6, 2026$19.01$19.01$18.055$18.201.02M

Latest ENOV news

The latest Smart Investors Daily articles mentioning ENOV.

ENOV research

Overview

Company profile and research snapshot.

Company profile

Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention & Recovery (P&R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention & Recovery segment, which includes products that are used to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports-related injuries. The Reconstructive segment provides a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and surgical productivity tools. Geographically, it derives key revenue from the U.S.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$64.50
Implied upside
—
Analysts
16
ENOV recent ratings
DateFirmRatingTarget
Oct 12, 2026NeedhamBuy—
Sep 2, 2026Wells FargoOverweight—
Sep 2, 2026CitizensMarket Outperform—
Sep 2, 2026Freedom Capital MarketsBuy—
Sep 2, 2026BTIGBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 24, 2026

Enovis (ENOV) Stock May Be 39% Undervalued On Cash Flow

Enovis shares have rebounded over the past month after a long slide, which naturally raises a sharper question for investors about whether the current price lines up with the cash the business is expected to generate. With the focus squarely on its cash flows, the issue is not just where the stock has come from, but what the present valuation assumes about the future of the company’s cash engine. The stock has fallen 76.3% over the past 5 years, which means today’s valuation is being asked...

Yahoo · Oct 23, 2026

1 value stock worth investigating and 2 we question

Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are usually cheap for a reason, and a low valuation can reflect underlying business challenges rather than a genuine bargain.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.